LGC Acquires Quotient’s Bioanalytical Business
News Jan 04, 2013
LGC and Quotient Bioresearch has announced that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.
Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.
The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.
Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences.
This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling.
The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.
The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.
Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”
Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”
Blood Sample Detection Method for Multiple Sclerosis DiscoveredNews
A method for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research team. The process will avoid the invasive, painful process of collecting fluid from the brain and spineREAD MORE
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE